ROG.VX - Roche Holding AG

Swiss - Swiss Delayed Price. Currency in CHF
272.55
+1.85 (+0.68%)
At close: 5:32PM CET
Stock chart is not supported by your current browser
Previous Close270.70
Open270.70
Bid272.70 x 243000
Ask271.00 x 260500
Day's Range270.20 - 272.90
52 Week Range206.35 - 272.90
Volume4,465,107
Avg. Volume1,120,466
Market Cap233.539B
Beta (3Y Monthly)N/A
PE Ratio (TTM)27.15
EPS (TTM)N/A
Earnings DateJan 26, 2016 - Feb 1, 2016
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est256.80
  • Jeffrey Gundlach talks millennials, national debt, and the race for 2020
    Yahoo Finance Video2 days ago

    Jeffrey Gundlach talks millennials, national debt, and the race for 2020

    DoubleLine CEO Jeffrey Gundlach talks about the millennial generation, the nation's debt and possible candidates for the 2020 presidential election, with Yahoo Finance's Julia La Roche.

  • Yahoo Finance's exclusive interview with DoubleLine CEO Jeffrey Gundlach
    Yahoo Finance Video4 days ago

    Yahoo Finance's exclusive interview with DoubleLine CEO Jeffrey Gundlach

    DoubleLine Capital CEO Jeffrey Gundlach shares his thoughts on market risks, the possibility of a recession, Fed policy and the 2020 election. He speaks exclusively with Yahoo Finance's Julia La Roche, Jen Rogers, Myles Udland and Andy Serwer.

  • Aurora earnings show concern for pot stocks
    Yahoo Finance Video5 days ago

    Aurora earnings show concern for pot stocks

    Aurora Cannabis reported earnings for its second quarter. The company says it accounted for about 20% of all consumer sales across Canada for the quarter. Yahoo Finance's Jackie DeAngelis and Julia La Roche discuss.

  • New Technology Is Making Selfies Obsolete
    Yahoo Finance Video6 days ago

    New Technology Is Making Selfies Obsolete

    Is it time to say goodbye to the travel selfie? Yahoo Finance's Zack Guzman & Julia La Roche, along with Frank CEO & Founder Charlie Javice, discuss with Flytographer CEO & Founder Nicole Smith.

  • This country's universal basic income experiment may surprise you
    Yahoo Finance Video6 days ago

    This country's universal basic income experiment may surprise you

    Yahoo Finance's Zack Guzman and Julia La Roche discuss one countries basic income experiment with Charlie Javice, Frank founder and CEO.

  • Should Amazon Be Worried About The Competition?
    Yahoo Finance Video16 days ago

    Should Amazon Be Worried About The Competition?

    When it comes to e-commerce Amazon is the biggest name in the game, but should the company be worried about losing its top spot? We discuss with Jen Rogers, Brian Sozzi, Julia La Roche, and Adam Johnson

  • Hulu introduces "Pause Ad" as alternative to commercials
    Yahoo Finance Video16 days ago

    Hulu introduces "Pause Ad" as alternative to commercials

    Hulu is changing how they advertise to subscribers by showing ads when users press pause. King's College Professor Brian Brenberg joins Yahoo Finance's Adam Shapiro, Dan Roberts, and Julia La Roche for a chat.

  • Exelixis, Inc (EXEL) Q4 2018 Earnings Conference Call Transcript
    Motley Fool5 days ago

    Exelixis, Inc (EXEL) Q4 2018 Earnings Conference Call Transcript

    EXEL earnings call for the period ending December 31, 2018.

  • ImmunoGen Still Waiting to Take Its Leap "Forward"
    Motley Fool5 days ago

    ImmunoGen Still Waiting to Take Its Leap "Forward"

    Data from a late-stage clinical trial is expected in the first half of this year.

  • The Wall Street Journal6 days ago

    A Flu Drug Was Called ‘Silver Bullet,’ but Some Doctors Prescribe Caution

    TOKYO—A new pill that can kill the flu virus in 24 hours with a single dose has become the most-prescribed influenza treatment in Japan, which is suffering through its worst flu season in two decades. The pill, called Xofluza, was discovered by Osaka-based Shionogi & Co. and it was approved last year by regulators in Japan and the U.S. In the U.S., it is marketed by Roche Holding AG’s Genentech unit. The drug quickly gained the top share in Japan, according to Shionogi’s data, in part because of its ease of use.

  • Benzinga6 days ago

    Fannie Mae And Freddie Mac Saw Massive Increases In Trading Volume In January

    Trading data from OTC Markets Group shows that shares of government-sponsored entities Fannie Mae and Freddie Mac saw a dramatic increase in dollar trading volume last month. Common shares of Fannie Mae ...

  • Thomson Reuters StreetEvents10 days ago

    Edited Transcript of ROG.VX earnings conference call or presentation 31-Jan-19 3:00pm GMT

    Full Year 2018 Roche Holding AG Earnings Call

  • Biotech Stock Rockets 130% As It Takes On Roche In Breast Cancer
    Investor's Business Daily11 days ago

    Biotech Stock Rockets 130% As It Takes On Roche In Breast Cancer

    Macrogenics stock rocketed by triple digits Wednesday after the firm said its breast cancer treatment outperformed Roche's competing drug, the blockbuster Herceptin, in a late-stage study.

  • Barrons.com11 days ago

    Bristol-Myers Stock Could Get Hit By Donald Trump’s Drug-Price Plan

    Roche and Bristol-Myers Squibb are most exposed among large-cap pharmaceuticals firms to Medicare Plan B sales, notes Credit Suisse.

  • Roche, joining rivals, donates hemophilia drug to boost access
    Reuters11 days ago

    Roche, joining rivals, donates hemophilia drug to boost access

    Switzerland's Roche will donate its new hemophilia A drug Hemlibra to a World Hemophilia Federation program, it said on Wednesday, joining rivals who also back the effort to help patients in developing countries who face treatment hurdles. Roche's donation will focus on patients who have developed resistance, or inhibitors, to current hemophilia A treatments as well as children, the Basel-based company said in a statement. Roche joins other companies including Sanofi's Bioverativ, Sobi, CSL Behring and Grifols that also have made contributions to the World Hemophilia Federation (WHF) Humanitarian Aid Program, which said it helped more than 16,000 patients in 60 countries in 2017.

  • How Much Did Roche Holding AG’s (VTX:ROG) CEO Pocket Last Year?
    Simply Wall St.12 days ago

    How Much Did Roche Holding AG’s (VTX:ROG) CEO Pocket Last Year?

    Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! In 2008 Severin Schwan was appointed CEO Read More...

  • Benzinga12 days ago

    The Daily Biotech Pulse: Gilead Earnings, Codexis Sings Pact With Merck, Eli Lilly Reports Positive Trial Results

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Feb. 4) AEterna Zentaris Inc. (NASDAQ: AEZS ) Axsome Therapeutics ...

  • Reuters12 days ago

    Roche adapts newer breast cancer drug in face of Herceptin imitations

    Swiss drugmaker Roche aims to broaden the use of its Kadcyla breast cancer treatment as rivals crowd into the market with biosimilar copies of its older mainstay Herceptin. Roche said on Tuesday it had applied for U.S. Food and Drug Administration approval for Kadcyla, a five-year-old drug, for post-surgical use in women with a form of early stage breast cancer who still show signs of disease after treatment with Herceptin and chemotherapy.

  • Benzinga17 days ago

    The Daily Biotech Pulse: Hologic, Celgene Earnings, FDA To Rule On Alkermes Depression Drug

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Jan. 30) Varian Medical Systems, Inc. (NYSE: VAR ) EXACT Sciences ...

  • The Wall Street Journal17 days ago

    [$$] European Equities Market Talk Roundup

    ’s fourth-quarter net profit should decline to 82 million euros from EUR147.7 million a year earlier, according to a consensus forecast provided by FactSet. Credit Suisse analysts expect the Spanish bank to report a core tier 1 ratio of 11.1% at the end of December, up from 11.0% in September. Swatch’s 2018 EBIT fell 10% short of UBS analysts’ expectations and its organic growth flatlined in 2H, UBS says.

  • The Wall Street Journal18 days ago

    [$$] Roche Upbeat After Strong 2018 Results

    Roche said its 2018 net profit rose 23%, with increases in sales at both its pharmaceuticals and diagnostics divisions.

  • Roche sees 2019 sales, profit rise despite competition from copies
    Reuters18 days ago

    Roche sees 2019 sales, profit rise despite competition from copies

    Roche expects sales and earnings to rise in 2019 as new drugs more than offset competition from copies of its $20 billion-plus per year trio of cancer medicines Rituxan, Herceptin and Avastin, the Swiss drugmaker said on Thursday. Core operating profit last year climbed 9 percent to 20.5 billion Swiss francs ($20.65 billion), the company said. Roche shares were indicated 1.2 percent higher.

  • CNBC18 days ago

    Roche posts 2018 sales beat with strong growth from its new medicines

    Swiss health care giant Roche reported a 7 percent rise in 2018 sales on Tuesday, highlighting strong demand for its new range of medicines.

  • Roche Scraps Alzheimer's Test — But Investors Punished This Stock
    Investor's Business Daily18 days ago

    Roche Scraps Alzheimer's Test — But Investors Punished This Stock

    Biogen stock slipped Wednesday after Roche and AC Immune opted to scrap two Alzheimer's treatment studies — leading investors to look for details of Biogen's own experimental drug.